Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
91. |
ECCT/17/08/09 | A trial to compare two new combinations of antimalarial drugs with the standard combination of antimalarial drugs in Kenyan children An open-label randomised trial to assess the therapeutic efficacy and tolerability of arterolane-piperaquine plus single low dose primaquine versus arterolane-piperaquine plus mefloquine and single low dose primaquine versus artemether-lumefantrine plus single low dose primaquine in the treatment of uncomplicated falciparum malaria in children in Kenya. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya 1. Kilifi County Hospital - Paediatric Out patient and Inpatient department (Kilifi county) 2. Pingilikani Dispensary (Kilifi county) |
04-01-2018 |
View |
92. |
ECCT/17/09/03 | A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Deborah Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre |
14-11-2017 |
View |
93. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
10-10-2017 |
View |
94. |
ECCT/17/08/03 | Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya KEMRI Siaya |
02-10-2017 |
View |
95. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
07-07-2017 |
View |
96. |
ECCT/16/11/02 | IMPAACT P1093 Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Principal Investigator(s) 1. Lucy Koech Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME |
28-03-2017 |
View |
97. |
ECCT/16/05/03 | Clinical trial of neem & coconut oils for tungiasis Phase IIA, randomised controlled trial of a locally-made, herbal remedy (neem & coconut oil) for treatment of jiggers (Tunga penetrans) |
Principal Investigator(s) 1. Ulrike Fillinger Site(s) in Kenya Dabaso Tujengane CBO |
28-03-2017 |
View |
98. |
ECCT/16/11/05 | RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo. |
Principal Investigator(s) 1. Fredrick Kipyego Sawe Site(s) in Kenya 1. KEMRI/WRP Kericho (Kericho county) 2. KEMRI/WRP Kombewa, Kisumu (Kisumu county) |
02-03-2017 |
View |
99. |
ECCT/16/10/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Professor Walter Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Research (Nairobi City county) 2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) |
13-02-2017 |
View |
100. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
28-01-2017 |
View |